Blog - Page 3 of 5627 - QualityStocks

MondayMay 11, 2026 1:40 pm

QualityStocksNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Next-Generation GLP-1 Candidate as Obesity Drug Market Expands Rapidly

This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF), through subsidiary GlucaPharm Inc., is advancing GEP-44, a patented triple agonist peptide targeting GLP-1 and peptide YY receptors as the global obesity and metabolic disease market continues to expand. The company is pursuing a differentiated approach focused on improved efficacy, tolerability and delivery flexibility in a therapeutic category that has become one of the most commercially significant in modern healthcare, with long-term market projections exceeding $200 billion. SureNano is part of an increasingly competitive GLP-1 landscape led by Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen…

MondayMay 11, 2026 1:31 pm

QualityStocksNewsBreaks – SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) Targets Defense Autonomy Software Opportunity as AI-Driven Drone Warfare Accelerates

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising. SPARC AI (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) is positioning itself at the center of a major shift in modern warfare, where the rapid proliferation of low-cost drones is driving demand for software-defined autonomy capable of operating in contested environments without GPS or continuous human control. Through its Overwatch platform, the company is developing a software-only system designed to provide GPS-denied navigation and precision targeting across existing drone fleets, addressing a growing operational gap as defense agencies increasingly prioritize scalable autonomous systems. SPARC AI is part of a broader…

MondayMay 11, 2026 1:18 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Launches Pilot Study for On-Demand 12-Lead ECG Patch in Coronary Artery Disease Patients

HeartBeam (NASDAQ: BEAT) announced the initiation of a pilot study evaluating its investigational on-demand 12-lead ECG patch in approximately 50 patients with suspected coronary artery disease at two hospitals in Belgrade, Serbia. The study will compare synthesized 12-lead ECG readings generated by the company’s patch immediately following exercise stress testing against standard 12-lead ECGs, supporting HeartBeam’s regulatory strategy for a device designed to expand ambulatory cardiac monitoring beyond rhythm assessment into ischemia detection within an established approximately $2 billion patch-based monitoring market. To view the full press release, visit https://ibn.fm/j2bEo About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring…

MondayMay 11, 2026 1:06 pm

QualityStocksNewsBreaks – Datavault AI Inc. (NASDAQ: DVLT) Highlights Edge Computing Strategy Ahead of Senate Digital Asset Legislation Vote

Datavault AI (NASDAQ: DVLT) highlighted the strategic positioning of its distributed edge computing network ahead of this week’s anticipated U.S. Senate Banking Committee markup of the Digital Asset Market Clarity Act, legislation aimed at establishing a comprehensive federal framework for digital assets. The company said it expects regulatory clarity to support increased demand for secure data processing, tokenization and AI infrastructure, as it advances deployment of a modular mini data center network targeting more than 100 U.S. metropolitan markets with full commercial availability of a planned 48,000-GPU fleet beginning in the third quarter of 2026. To view the full press release, visit https://ibn.fm/0ts3j About Datavault AI Datavault AI(TM) (NASDAQ: DVLT)…

MondayMay 11, 2026 12:00 pm

QualityStocksNewsBreaks – Twin Vee PowerCats Co. (NASDAQ: VEEE) Reports Revenue Growth in First Quarter 2026, Advances Bahama Brand Expansion

Twin Vee PowerCats (NASDAQ: VEEE)reported first-quarter 2026 revenue growth of approximately 10% year over year and 31% sequentially, marking its fourth consecutive quarter of year-over-year revenue gains, as the company continued expanding its product lineup with the relaunch of Bahama Boat Works. Twin Vee posted a net loss of $2.09 million, compared with $1.6 million in the prior-year quarter, while adjusted EBITDA loss improved 11% to $776,000. The company said results included approximately $1.3 million in non-cash and one-time items tied to inventory adjustments, product development and field inventory management, while cash and equivalents increased by more than $4 million…

MondayMay 11, 2026 11:15 am

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Toward Clinical Stage with IND-Enabling Program for GLP GEP-44

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement. SureNano Science initiated an FDA-aligned IND-enabling GLP toxicology and pharmacology program for lead candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes, positioned within the growing GLP-1 therapeutic market as a minnow among giants. The studies will assess safety, dosing thresholds, and pharmacological effects across multiple species, GEP-44 preclinical results position it head-to-head with leaders such as Ozempic, Mounjaro, Wegovy. The program is expected to support a Phase I clinical trial in Australia, subject to regulatory submission and study outcomes. The…

MondayMay 11, 2026 10:40 am

QualityStocksNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Expands AI Voice Diagnostics Platform With Fatigue Detection Technology

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced the development of AI-powered fatigue recognition technology that analyzes voice patterns and is intended to be added as a commercial feature to the company’s Edge AI Intoxication Detection Kiosks. Designed for high-risk industries including aviation, road transport and mining, the fatigue detection module complements MindBio’s broader voice-based diagnostics platform aimed at identifying intoxication and neurological impairment, with initial commercial testing of the kiosk platform expected in late second quarter 2026. To view the full press…

MondayMay 11, 2026 10:30 am

The Partnership Playbook: Oncotelic Therapeutics Inc. (OTLC) Advancing Its Pipeline Without Dilution

The GMP Bio joint venture contributed a $249 million increase to Oncotelic’s balance sheet through independent third-party valuation The company is leveraging a deep intellectual property portfolio, including more than 500 patent applications and 75 issued patents Oncotelic’s PDAOAI platform has integrated approximately 28 million scientific abstracts and is advancing toward commercial deployment with robotics integration In clinical-stage biotechnology, the central challenge is rarely scientific discovery. It is capital. Advancing multiple therapeutic candidates through preclinical work, clinical trials, and regulatory approval requires sustained funding, and traditional financing routes often come at the cost of dilution or loss of asset control.…

MondayMay 11, 2026 10:00 am

QualityStocksNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Advances AI Voice-Based Intoxication Detection as Real-Time Diagnostics Market Expands

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) is developing an AI-driven voice analysis platform designed to detect drug and alcohol intoxication in real time, addressing growing demand for faster, scalable and noninvasive impairment detection across workplace safety, healthcare and public safety markets. By leveraging speech as a diagnostic biomarker, the company is pursuing a differentiated approach to multisubstance intoxication detection within an evolving AI healthcare landscape that includes HeartFlow Inc. (NASDAQ: HTFL), Recursion Pharmaceuticals Inc. (NASDAQ: RXRX), Tempus AI Inc. (NASDAQ: TEM) and…

MondayMay 11, 2026 9:50 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Targets CNS Drug Delivery Opportunity as Brain Therapeutics Innovation Accelerates

Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself within a growing push to overcome one of modern medicine’s most persistent challenges: delivering therapeutics effectively across the blood-brain barrier. Through its proprietary intranasal nose-to-brain delivery platform, the company is pursuing targeted central nervous system applications spanning Alzheimer’s disease and biodefense, reflecting broader industry recognition that delivery technology may be as critical as drug discovery itself. Oncotelic is part of an innovative therapeutic landscape that includes Biogen Inc. (NASDAQ: BIIB), Moderna Inc. (NASDAQ: MRNA), CytoDyn Inc. (OTCQB: CYDY) and Northwest Biotherapeutics Inc. (OTCQB: NWBO). As the global burden of neurodegenerative disease rises and…

Site Search

Company Search